Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Swan

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05622344Not ApplicableRecruiting

StableEyes With Active Neurofeedback

NCT06431984Not ApplicableCompleted

Pharmacology Space Kit (PSK) - Dried Blood Spot for Caffeine Pharmacokinetics Under Microgravity Conditions

Showing all 2 trials

Research Network

Common Treatments

  • Swan1
  • Traditional Therapy1
  • Prick Test1

Active Sponsors

  • Institut National de la Santé Et de la Recherche Médicale, France1
  • Johns Hopkins University1
  • National Aeronautics and Space Administration (NASA)1

Top Investigators

Related Conditions

  • Vestibular Schwannoma1
  • Metabolism Medication Toxicity1
  • Vestibular Disorder1
  • Motion Sickness1
  • Drug Mechanism1

Activity Timeline